Remarkably, studies of the radiolabeled [177Lu]Lu-scFv-D2B clearly showed good pharmacokinetics and greater affinity for PSMA in vitro and in vivo than the radiolabeled Glu-ureido-based PSMA inhibitors [95,96], making it a promising candidate for PCa early diagnosis [94]. Here, FOLH1 is linked to posterior cortical atrophy.